Health Care Delivery

What We’re Reading, April 29, 2016: While sales of Gilead's Harvoni drop, NY state attorney's decision could be good news for the company; and the FDA faces a lawsuit from a consumer advocacy group.

A company in Canada, Biolyse Pharma, has offered to manufacture a generic version of enzalutamide at a significantly lower price than what CMS paid in 2014.

Panel participants provide their perspectives on how they would like to see the field of oncology clinical pathways develop.

Panelists explain the need and the challenges with including principles of palliative care in oncology clinical pathways.

Robert Dubois, MD, PhD, shares findings from their recently published study in The American Journal of Managed Care, which showed that patients do not know they are being treated on predetermined pathways.

Neither Blase Polite, MD, MPP, not Robert Dubois, MD, PhD, believe that clinical pathways restrict patient access to care.

According to Blase Polite, MD, MPP, pathways are well-designed to allow personalized medicine.

According to Blase Polite, MD, MPP, it is much harder for a cancer center to adapt care pathways than it is for a smaller clinic.

Expanding the definition of "value" beyond cost, Robert Dubois, MD, PhD, emphasized that clinical pathways need more dynamic quality metrics that provide more than just a snapshot of a patient's performance.

Panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.